Friday, 16 October 2026European Markets

ADOCIA Stock Went Up By Over 20% In The Last 10 Sessions

Loading stream...

(vianews) - shares of adocia (cac 40: adoc.pa) rose by a staggering 20.92% in 10 sessions from €3.27 to €3.96 at 17:37 est on thursday, after five sequential sessions in a row of losses. cac 40 is jumping 0.16% to €7,214.16, following the last session's downward trend.

adocia's last close was €3.96, 38.7% below its 52-week high of €6.46.

about adocia

adocia sa, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. its proprietary biochaperone technological platform provides molecular delivery of therapeutic proteins. the company's clinical product pipeline includes insulin formulations, such as biochaperone lispro u100 and u200, which are ultra-rapid formulations based on rapid insulin lispro; biochaperone combo, a combination of acting insulin glargine and rapid-acting insulin lispro; biochaperone lispram, a combination of prandial insulin with pramlintide; and biochaperone glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as m1pram, a metabolite of insulin glargine and pramlintide. its preclinical pipeline includes products for the treatment of diabetes and obesity comprising adoshell islets, an implant containing islets of langerhans; adoral sema, an oral delivery of semaglutide; and biochaperone gluexe, a combination of glucagon and exenatide. the company has a strategic alliance with tonghua dongbao pharmaceutical co., ltd. to develop and commercialize biochaperone lispro and biochaperone combo in china and other asian and middle eastern territories. adocia sa was incorporated in 2005 and is headquartered in lyon, france.

earnings per share

as for profitability, adocia has a trailing twelve months eps of €-0.99.

revenue growth

year-on-year quarterly revenue growth grew by 312.1%, now sitting on 13.95m for the twelve trailing months.

yearly top and bottom value

adocia's stock is valued at €3.96 at 17:37 est, way under its 52-week high of €6.46 and way higher than its 52-week low of €2.80.

volume

today's last reported volume for adocia is 61713 which is 19.2% above its average volume of 51391.

moving average

adocia's value is way higher than its 50-day moving average of €3.58 and higher than its 200-day moving average of €3.96.

more news about adocia (adoc.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com